Search Results - "Linton, K M"

Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours by Linton, K M, Hey, Y, Saunders, E, Jeziorska, M, Denton, J, Wilson, C L, Swindell, R, Dibben, S, Miller, C J, Pepper, S D, Radford, J A, Freemont, A J

“…Robust protocols for microarray gene expression profiling of archival formalin-fixed paraffin-embedded tissue (FFPET) are needed to facilitate research when…”
Get full text

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE by Falchi, L., Clausen, M. R., Offner, F., Vos, S., Brody, J., Linton, K. M., Snauwaert, S., Cordoba, R., Wu, J., Bykhovski, I., Wang, L., Rana, A., Belada, D.

Get full text

Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial by Trotman, J., Tedeschi, A., Hu, B., Linton, K. M., McKay, P., Leitch, S., Jin, J., Sun, M., Sobieraj‐Teague, M., Zinzani, P. L., Browett, P., Thieblemont, C., Liberati, A. M., Bachy, E., Cavallo, F., Costello, R., Iyengar, S., Marasca, R., Mociková, H., Kim, J. S., Talaulikar, D., Liang, Z., Xu, J., Tankersley, C., Delarue, R., Co, M., Opat, S.

Get full text

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL by Thieblemont, C., Karimi, Y., Jurczak, W., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Cottereau, A., Al Tabaa, Y., Stirner, M. Cota, Liu, Y., Kilavuz, N., Sacchi, M., Lugtenburg, P., Ghesquieres, H.

Get full text

Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage by Santarsieri, A., Mitchell, E., Sanghvi, R., Lee‐Six, H., Sturgess, K., Brice, P., Menne, T., Osborne, W., Creasey, T., Ardesnhna, K. M., Behan, S., Bhuller, K., Booth, S., Chavda, N. D., Collins, G., Culligan, D., Cwynarski, K., Davies, A., Downing, A., Dutton, D., Furtado, M., Gallop‐Evans, E., Hodson, A., Hopkins, D., Hsu, H., Iyengar, S., Jones, S. G., Linton, K. M., Lomas, O. C., Martinez‐Calle, N., Mathur, A., McKay, P., Nagumantry, S. K., Phillips, E. H., Phillips, N., Rudge, J. F., Shah, N. K., Stafford, G., Sternberg, A., Trickey, R., Uttenthal, B. J., Wetherall, N., Zhang, X., McMillan, A. K., Rahbari, R., Stratton, M., Laurenti, E., Borchmann, S., Borchmann, P., Campbell, P. J., Follows, G. A.

Get full text

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE by Belada, D., Leppä, S., Wahlin, B. E., Nijland, M., Christensen, J. H., Vos, S., Holte, H., Linton, K. M., Abbas, A., Wang, L., Dinh, M., Elliott, B., Falchi, L.

Get full text

P1214: SUBCUTANEOUS EPCORITAMAB + R‐CHOP FOR FIRST‐LINE TREATMENT OF PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE 1/2 UPDATE by Clausen, M. R., Offner, F., Belada, D., Brody, J., Linton, K. M., Karimi, Y., Cordoba, R., Snauwaert, S., Abbas, A., Wang, L., Wu, J., Elliott, B., Falchi, L.

Get full text

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY by Opat, S., Hu, B., Tedeschi, A., Linton, K. M., McKay, P., Chan, H., Jin, J., Sun, M., Sobieraj-Teague, M., Zinzani, P. L., Coleman, M., Browett, P., Ke, X., Portell, C. A., Thieblemont, C., Ardeshna, K., Bijou, F., Walker, P., Hawkes, E. A., Ho, S.-J., Zhou, K.-S., Co, M., Xu, J., Liang, Z., Anderson, J., Tankersley, C., Huang, J., Trotman, J.

Get full text

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS by Belada, D., Falchi, L., Leppä, S., Vermaat, J. S., Holte, H., Hutchings, M., Lugtenburg, P., de Vos, S., Abrisqueta, P., Nijland, M., Merryman, R. W., Christensen, J. H., Wahlin, B. E., Linton, K. M., Wang, L., Abbas, A., Rana, A., Quadri, S., Sureda, A.

Get full text

Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases by Linton, K M, Taylor, M B, Radford, J A

“…Imatinib is a highly effective treatment for patients with metastatic gastrointestinal stromal tumours (GIST). In most instances, response to imatinib…”
Get full text

Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours by Linton, K M, Hey, Y, Saunders, E, Jeziorska, M, Denton, J, Wilson, C L, Swindell, R, Dibben, S, Miller, C J, Pepper, S D, Radford, J A, Freemont, A J

Get full text

P6238International cardiovascular disease risk calculators do not identify high risk in young hodgkin lymphoma survivors by Piddock, K, Britton, F, Goode, V, White, E, Greenstein, A, Linton, K M, Radford, J

“…Abstract Background Cardiotoxic therapy causes significant morbidity and mortality in patients (pts) treated for Hodgkin lymphoma (HL). Cardiovascular (CVS)…”
Get full text

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS by Belada, D., Falchi, L., Leppä, S., Vermaat, J. S., Holte, H., Hutchings, M., Lugtenburg, P., Vos, S., Abrisqueta, P., Nijland, M., Merryman, R. W., Christensen, J. H., Wahlin, B. E., Linton, K. M., Wang, L., Abbas, A., Rana, A., Quadri, S., Sureda, A.

Get full text

EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL by Vose, Julie, Vitolo, Umberto, Lugtenburg, Pieternella, Chamuleau, Martine E.D., Linton, Kim M., Thieblemont, Catherine, Sonnevi, Kristina, Jurczak, Wojciech, Olszewski, Adam J., Awan, Farrukh Tauseef, Okada, Craig Y., Feldman, Tatyana A, Hutchings, Martin, Favaro, Elena, Hoehn, Daniela, Li, Zhu, Conlon, Rebekah, Sancho, Juan-Manuel, Chavez, Julio C.

“…7015 Background: Improving the safety of epcoritamab by reducing the incidence and severity of CRS and ICANS may enhance its accessibility and reduce…”
Get full text

Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial by Linton, Kim M, Wahlin, Björn, Leepä, Sirpa, Morschhauser, Franck, Elliot, Brian, Liu, Tracy, Cota Stirner, Mariana, Abbas, Aqeel, Falchi, Lorenzo

“…Background: Patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL) develop increasingly aggressive disease and are at increased risk for…”
Get full text

Epcoritamab + R 2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status by Merryman, Reid, Belada, David, Sureda, Anna, Leppä, Sirpa, Vermaat, Joost S.P., Holte, Harald, Hutchings, Martin, Lugtenburg, Pieternella, de Vos, Sven, Abrisqueta, Pau, Nijland, Marcel, Christensen, Jacob Haaber, Wahlin, Björn E., Linton, Kim M., Wang, Liwei, Abbas, Aqeel, Rana, Ali, Quadri, Syed, Falchi, Lorenzo

“…7506 Background: Follicular lymphoma (FL) is a heterogeneous disease. Early progression after initial treatment (tx) with chemoimmunotherapy (CIT), POD24,…”
Get full text

Personalised therapy in follicular lymphoma - is the dial turning? by Linton, Kim M, Specht, Lena, Pavlovsky, Astrid, Thompson, Carrie A, Kimby, Eva, de Jong, Daphne, Nastoupil, Loretta J, Cottereau, Anne-Ségolène, Casulo, Carla, Sarkozy, Clémentine, Okosun, Jessica

“…Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries…”
Get full text

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY by Opat, S., Hu, B., Tedeschi, A., Linton, K. M., McKay, P., Chan, H., Jin, J., Sun, M., Sobieraj‐Teague, M., Zinzani, P. L., Coleman, M., Browett, P., Ke, X., Portell, C. A., Thieblemont, C., Ardeshna, K., Bijou, F., Walker, P., Hawkes, E. A., Ho, S.‐J., Zhou, K.‐S., Co, M., Xu, J., Liang, Z., Anderson, J., Tankersley, C., Huang, J., Trotman, J.

Get full text

Response evaluation in GIST treated with imatinib - misdiagnosis of disease progression on CT due to cystic change in liver metastases by Linton, K. M., Taylor, M. B., Radford, J. A.

“…Abstract only…”
Get full text

Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results by Linton, KM, Wahlin, B, Leppa, S, Morschhauser, F, Elliott, B, Liu, T, Stirner, MC, Abbas, A, Falchi, L

Get full text